Imperial Brands: Neutral Performance with Positive Investor Sentiment

Business by 2FIRSTS.ai

Jan.23.2024

Imperial Brands: Neutral Performance with Positive Investor Sentiment

According to German media aktiencheck, the 200-day moving average of Imperial Brands stock is currently at £1798.17.

According to reports from German media outlet Aktiencheck on January 23, the 200-day moving average for Imperial Brands' stock currently stands at £1798.17. Considering that the current stock price stands at £1881, this indicates a gap of +4.61%. Compared to other stocks in the consumer goods sector, Imperial Brands' earnings last year were 6% lower than the average level. However, within the tobacco industry, the stock's earnings outperformed the average level by 3.38%. As a result, the overall assessment is deemed to be "neutral".

It is worth noting that the 50-day moving average price stands at £1,836.3 with a corresponding difference of +2.43%, further reinforcing the "neutral" assessment.

Based on investor sentiment, there is currently a relatively positive attitude towards the Empire brand, with 12 positive and 1 negative feedbacks recorded recently. Considering the company's latest developments showing a proactive performance, the overall sentiment analysis rates it as "good".

References:

[1] Imperial Brands Aktie: Quo vadis?

Also Read:

[1] BLU Launches E-Liquid Brand "blu liquid" in UK

[2] Analysis of Imperial Tobacco Stock: Good Rating, Neutral Outlook

#Europe #Traditional tobacco #Market #Imperial Brands #Germany #Brands

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

British American Tobacco’s Irish unit says VELO pouch sales hit 29m, net revenue climbs to €33.75m

British American Tobacco’s Irish subsidiary PJ Carroll & Co Ltd reported that sales of its Velo nicotine pouches nearly quintupled in 2024 to 29 million units, driving an 11% year-on-year increase in net revenue to €33.75 million. However, amid a heavy tax burden and declining traditional cigarette volumes, the company’s pre-tax profit fell 8% to €5.69 million.

Dec.01 by 2FIRSTS.ai

Canadian Media Investigation: BAT’s Nicotine Pouch ZONNIC Sparks Ongoing Controversy as Regulatory Gaps in Canada Come Under Scrutiny

Canadian outlet Rebel News released a long-form video report examining Canada’s regulatory framework for nicotine pouches, market dynamics, and the approval process of ZONNIC, a product of BAT subsidiary Imperial Tobacco Canada. The report highlights issues involving youth access, regulatory gaps, black-market activity, retailer feedback, and company responses. This article summarizes key points based on the video.

Dec.02 by 2FIRSTS.ai

Philippine FDA Requires Licenses for Vape Products with Medical Claims

The Philippine Food and Drug Administration has announced that establishments selling vaporized nicotine and non-nicotine products and novel tobacco products with medicinal or therapeutic claims must secure Licenses to Operate. Such products are also required to be registered as pharmaceutical products through the Center for Drug Regulation and Research. The FDA urged stakeholders to comply with the new requirements to ensure product safety, efficacy and quality.

Dec.22 by 2FIRSTS.ai

BAT Expects Around 2% Revenue and Operating Profit Growth in FY25

British American Tobacco (BAT) reaffirmed its 2026 guidance while announcing a £1.3 billion (approximately USD 1.65 billion) share buyback for FY26. The company expects around 2% growth in revenue and adjusted profit from operations for FY25. Accelerating New Category growth, driven by Velo Plus and improving U.S. Vuse performance, is expected to deliver double-digit H2 revenue growth.